Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic

[1] Wouters OJ(2021)Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment The Lancet 397 1023-1034

[2] Shadlen KC(2018)Health systems development in Thailand: a solid platform for successful implementation of universal health coverage The Lancet 391 1205-1223

[3] Salcher-Konrad M(2020)Modelling the COVID-19 pandemic in context: an international participatory approach BMJ Glob Health 5 212-830

[4] Pollard AJ(2020)Contact tracing for tuberculosis Thailand 98 820-1443

[5] Larson HJ(2021)Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis J. Med. Virol. 93 1441-111

[6] Teerawattananon Y(2021)Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? The Lancet 397 99-1423

[7] Tangcharoensathien V(2021)Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Lancet 397 1412-1735

[8] Witthayapipopsakul W(2020)Will covid-19 vaccines save lives? Current trials aren’t designed to tell us BMJ 371 1725-500

[9] Panichkriangkrai W(2021)BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting N. Engl. J. Med. 384 495-1546

[10] Patcharanarumol W(2021)COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study Lancet 397 1532-775

[1] Wouters OJ(2021)Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment The Lancet 397 1023-1034

[2] Shadlen KC(2018)Health systems development in Thailand: a solid platform for successful implementation of universal health coverage The Lancet 391 1205-1223

[3] Salcher-Konrad M(2020)Modelling the COVID-19 pandemic in context: an international participatory approach BMJ Glob Health 5 212-830

[4] Pollard AJ(2020)Contact tracing for tuberculosis Thailand 98 820-1443

[5] Larson HJ(2021)Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis J. Med. Virol. 93 1441-111

[6] Teerawattananon Y(2021)Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? The Lancet 397 99-1423

[7] Tangcharoensathien V(2021)Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Lancet 397 1412-1735

[8] Witthayapipopsakul W(2020)Will covid-19 vaccines save lives? Current trials aren’t designed to tell us BMJ 371 1725-500

[9] Panichkriangkrai W(2021)BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting N. Engl. J. Med. 384 495-1546

[10] Patcharanarumol W(2021)COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study Lancet 397 1532-775